Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
John Floyd
Observed names:
J Floyd,
J. Floyd,
JOHN L. FLOYD,
John L. Floyd,
John Robert Floyd
Institution:
The University of Texas at San Antonio Health Science Center
Observed institutions:
William Beaumont Army Medical Center,
The University of Texas at San Antonio Health Science Center,
Vanderbilt University,
Mays Cancer Center at UT Health San Antonio,
The University of Texas at San Antonio,
Vanderbilt University Medical Center
show all 6
ORCID:
0009-0004-7282-5818
Observed ORCID:
0009-0004-7282-5818
OpenAlex ID:
A5013185458
Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2023
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
·
Clinical Cancer Research
·
158
PDF
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study
2018
·
Andrew Brenner
, Richard Zuniga
, et al.
·
Neuro-Oncology
·
38
PDF
Proteomics in Diagnostic Neuropathology
2006
·
Mahlon D. Johnson
, John L. Floyd
, et al.
·
Journal of Neuropathology & Experimental Neurology
·
31
Ctni-36. Sacituzumab Govitecan for Recurrent Glioblastoma
2023
·
William Kelly
, Henriette Balinda
, et al.
·
Neuro-Oncology
·
1
PDF
Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Table S2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Figure S1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Figure S3 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Table S3 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Figure S2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Table S1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2025
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Ctni-67. Phase 1 Multicenter Study of Multiple Doses of Rhenium (186re) Obisbemeda (reyobiq) for Leptomeningeal Metastases: Rationale, Design, and Preliminary Cohort 1 Data
2025
·
Andrew Brenner
, Priya Kumthekar
, et al.
·
Neuro-Oncology
PDF
Ctni-43. Phase 1/2 Respect-gbm Trial of Rhenium (186re) Obisbemeda in Recurrent Glioblastoma: Safety and Efficacy From the Phase 1 and Update on Phase 2
2025
·
Andrew Brenner
, Michael Youssef
, et al.
·
Neuro-Oncology
PDF
205 Treatment of Recurrent Glioblastoma (rGBM) Via Convection Enhanced Delivery (CED) With Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL): ReSPECT-GBM Phase 2 Trial Update
2025
·
John Robert Floyd
, Toral R. Patel
, et al.
·
Neurosurgery
Data from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplementary Data File 2 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Table S1 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Figure S1 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Figure S2 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Table S2 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Table S3 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplementary Data File 1 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Figure S3 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Supplemental Figure S1 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
2024
·
William Kelly
, Adolfo Enrique Diaz Duque
, et al.
Show more works
View as search
Works count:
58
Citation count:
228
H-index:
3
I10-index:
3
Year
Topic
Type